Reacción a "Early administration of an anti-amyloid therapy could delay the onset of Alzheimer's disease"

The DIAN-TU platform was a key revolutionary approach to structuring such complex research as the analysis of therapies in familial cases of Alzheimer's disease. 

Current evidence indicates that disease-modifying treatments have greater efficacy in patients at earlier stages of the disease (and with less tau pathology in the brain). Phase 3 trials are currently evaluating drugs that eliminate amyloid much more effectively in the preclinical population with sporadic (non-familial) Alzheimer's disease. This is the case of trials with monoclonal antibodies such as donamemab or lecanemab, which will be completed in 2027 and 2028, respectively.  

The study now published is conducted with a molecule with worse pharmacodynamic properties than other molecules (e.g., lecanemab, donamemab, trontinemab, remternetug). The difficulty of recruitment for these studies in patients with familial Alzheimer's disease hampers the ability to observe significant differences between groups.